98%
921
2 minutes
20
Reliable detection of Aquaporin-4 (AQP4) antibodies is crucial for diagnosing Neuromyelitis Optica spectrum disorder (NMOSD). However, cell-based assays, the most reliable approach, are limited by inadequate instruments. This study reports the use of silver metal-organic gels (Ag-MOGs) as coreactants in a single-electrode electrochemical system (SEES)-based electrochemiluminescence (ECL) immunosensor for multiplex detection of AQP4 antibodies. The immunosensor was constructed by modifying the carbon nanotube single-electrode with Ag-MOGs, incubating it with AQP4 peptides, and ultimately enabling the immobilization of AQP4 antibodies. Voltage-induced potential gradients at the electrode triggered the Ru(bpy) ECL reaction, and reduced emissions caused by AQP4 antibodies were recorded using a smartphone. Under optimal conditions, the immunosensor exhibited a strong linearity (10-1000 ng/mL) with a detection limit of 2.8 ng/mL. Validation of its accuracy, precision, dilutability, and selectivity confirmed robust performance across the diverse parameters. Furthermore, it successfully detected AQP4 antibodies in serum samples from seropositive NMOSD patients. The platform's single electrode design and multiplex capability make it simple, fast and cost-effective. Enhanced accessibility and user-friendliness could position this system as a transformative tool for improving disease diagnosis and treatment, particularly in resource-limited regions.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bios.2025.117128 | DOI Listing |
Clin Neurol Neurosurg
October 2025
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
We present the case of a 54-year-old patient treated with cemiplimab, an immune checkpoint inhibitor (ICI), for multiple basal cell carcinomas in the context of Gorlin Goltz syndrome. Gorlin Goltz syndrome is an autosomal dominant multisystem disorder characterized, among other features, by multiple early-onset basal cell carcinomas (BCCs). After receiving Cemiplimab, she developed aquaporin-4 antibody (AQP4-Ab) positive neuromyelitis optica spectrum disorder (NMOSD).
View Article and Find Full Text PDFAnn Clin Transl Neurol
September 2025
Experimental and Clinical Research Center, a Cooperation Between Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité-Universitätsmedizin Berlin, Berlin, Germany.
Objective: Soluble interleukin-2 receptor (sIL-2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) pathogenesis. However, sIL-2R has so far not been evaluated in these conditions.
View Article and Find Full Text PDFMult Scler Relat Disord
August 2025
Clinic of Neurology, University Clinical Center of Serbia, Dr Subotica 6, 11000 Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000 Belgrade, Serbia. Electronic address:
Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the central nervous system, mediated by antibodies against aquaporin 4 (AQP4-IgG) in 80 % of cases. The aim of the study was to estimate the prevalence of NMOSD and incidence over a twelve-year study period (2013-2024), in Serbia.
Methods: This study comprises data from 146 NMOSD patients, diagnosed according to the NMOSD criteria 2015.
Mol Ther
September 2025
Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China. Electronic address:
Neuromyelitis Optica spectrum disorder (NMOSD) is a relapsing autoimmune disease primarily affecting the optic nerves and spinal cord. While the pathogenesis of NMO involves Aquaporin-4 antibodies (AQP4-IgG) and complement-mediated damage, the specific roles of the complement pathway remain to be fully elucidated. In this study, we found that complement factor H-related protein 2 (CFHR2), a regulator that inhibits the complement C3 alternative pathway, was significantly decreased in the serum of NMO patients and was negatively correlated with the Expanded Disability Status Scale (EDSS) score.
View Article and Find Full Text PDFMov Disord Clin Pract
September 2025
Division of Neurology, Hospital Universitário Walter Cantídio, Universidade Federal do Ceará, Fortaleza, Brazil.
Background: Several movement disorders (MD) have been reported to occur in neuromyelitis optica spectrum disorder (NMOSD). No extensive review has addressed the whole spectrum of MD in NMOSD.
Objective: This article aims to review MD in NMOSD, describing its prevalence and features.